Moderna to Supply Up to 125 Million COVID-19 Vaccine Doses in Q1 2021

American biotechnology company Moderna said on Thursday it expects to have between one hundred million and one hundred twenty-five million doses of its experimental novel coronavirus disease vaccine available globally in the first quarter of the coming year.

The Cambridge, Massachusetts-based firm said eighty-five million to one hundred million of those doses would be available in the United States, with 15 million to 25 million available outside of the country.

The doses planned for production in the first-quarter are within the five hundred million to up to one billion doses the company expects to manufacture globally in 2021, Moderna said.

Results from an early-stage trial showed that the COVID-19 vaccine, mRNA-1273, produced high levels of binding and neutralizing antibodies that declined slightly over time, but remained elevated in all participants three months after the booster vaccination, the company said.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.